VIDEO: Oral S1P receptor modulator induces clinical remission in UC
Click Here to Manage Email Alerts
SAN DIEGO — In a Healio video exclusive, Marla C. Dubinsky, MD, discusses results from the ELEVATE UC trials, in which once daily etrasimod induced clinical remission in patients with ulcerative colitis.
“It was really exciting to see that we have yet another potential therapy that will be approved in this new class of small molecules known as S1P receptor modulators,” Dubsinky, professor of pediatrics and medicine at the Icahn School of Medicine at Mount Sinai and co-director of the Susan and Leonard Feinstein Clinical IBD Center, said. “We look forward to seeing what happens next with regard to this therapy being approved for ulcerative colitis.”
Results from the two phase 3 trials were presented at Digestive Disease Week 2022.
Collapse
Dubinsky M, et al. Abstract 968a. Presented at: Digestive Disease Week; May 21-24, 2022; San Diego (hybrid meeting).
Read more about
Click Here to Manage Email Alerts